Tesamorelin vs sermorelin: evidence, cost, and legality

Which is better, sermorelin or tesamorelin?

Tesamorelin wins on evidence (large phase 3 RCTs with a body composition endpoint, plus a 61 person RCT showing a 37% relative drop in liver fat in HIV) and on regulatory status (FDA approved since 2010, and Egrifta WR is available by prescription). Sermorelin's human data are small and hormonal, and it has had no marketed FDA approved product since 2009. The win applies to the approved HIV indication; off label use in people without HIV rests on one small trial for tesamorelin and none for sermorelin. [1] [5] [6] [7] [8] [15]

How do sermorelin and tesamorelin compare?

Sermorelin and Tesamorelin compared by dimension
Dimension	Sermorelin	TesamorelinFavored
Molecule [3] [7]	First 29 amino acids of human GHRH; plasma half life of minutes.	Full 44 amino acid GHRH analog with an N-terminal trans-3-hexenoic acid group that resists dipeptidyl peptidase cleavage, extending action.
Best human evidence [1] [5]	Single blind, placebo controlled trial in 19 adults aged 55 to 71 for 16 weeks: higher nocturnal GH and IGF-1, thicker skin, lean mass and insulin sensitivity gains in men only.	Pooled phase 3 trials in 806 adults with HIV: visceral fat minus 24 versus plus 2 cm2 at 26 weeks (treatment effect minus 15.4%) and triglycerides minus 37 versus plus 6 mg/dL.
Liver and metabolic evidence [1] [6]	No liver or visceral fat trial; transient hyperlipidemia in the adult trial.	HIV with fatty liver (61 adults, 12 months): hepatic fat fraction down an absolute 4.1% (37% relative); 35% versus 4% reached normal liver fat, with no glucose or HbA1c difference.
FDA status [8] [12]	No currently approved product. Geref was approved in 1990 (diagnostic) and 1997 (pediatric GH deficiency), withdrawn in 2009; FDA found in 2013 this was not for safety or effectiveness.	FDA approved as Egrifta (2010), Egrifta SV (2019), and Egrifta WR (2025) to reduce excess abdominal fat in adults with HIV associated lipodystrophy.
Compounding status [9] [10] [16]	Not on Category 2 or the bulks list; 503A pharmacies compound it based on the former approval, a reading that depends on the state board.	Biologic since March 2020 (BLA 022505), so it is not eligible for 503A or 503B compounding; Egrifta WR by prescription is the only lawful product.
Label or literature dosing [1] [4] [5] [12] [13]	Geref label: 30 ug/kg subcutaneously at bedtime in children. Adult trial: 10 ug/kg nightly.	FDA label: Egrifta WR 1.28 mg or Egrifta SV 1.4 mg injected under the skin of the abdomen once daily (the formulations are not substitutable); the phase 3 trials used 2 mg daily of the original Egrifta. Effect fades after stopping.
Side effects [2] [4] [7]	Injection site reactions, flushing, headache; rising fasting glucose and insulin in children; antibodies without apparent loss of effect.	Arthralgia (about 13%), injection site reactions, peripheral edema, myalgia, paresthesia; label advises monitoring glucose and IGF-1.
Typical cost [8] [12] [14] [16]	Compounded only, paid in cash through telehealth clinics that include the visit; there is no branded product. Dated prices are on the sermorelin cost page.	Egrifta WR has no published list price; one retail cash listing put a 28 day kit at about 10,709 USD (checked 2026-09-22). Compounded tesamorelin has no lawful price because tesamorelin is a biologic; dated prices are on the tesamorelin cost page.
Note: Prices at the verification date change often.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Sermorelin and Tesamorelin: grade, status, and cost
Attribute	Sermorelin	Tesamorelin
Class	Synthetic 29 amino acid N-terminal fragment of human growth hormone releasing hormone (GHRH 1-29), the shortest fragment with full GHRH receptor activity	Synthetic 44 amino acid analog of human growth hormone releasing hormone with an N-terminal trans-3-hexenoic acid modification that resists enzymatic degradation
What it is	Formerly FDA approved piece of growth hormone releasing hormone (Geref, withdrawn 2009 for business reasons); small trials show higher GH and IGF-1.	FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: Regulatory status unknown	Regulatory: FDA approved
Compounding	There is no currently approved sermorelin product in the United States. Geref (sermorelin acetate) was approved as a diagnostic on December 28, 1990 (NDA 19-863) and for treatment of idiopathic growth hormone deficiency in children on September 26, 1997 (NDA 20-443); the sponsor discontinued both in 2008 and FDA withdrew the approvals effective June 18, 2009. In March 2013 FDA determined in the Federal Register that Geref was not withdrawn for reasons of safety or effectiveness, which allows generic applications. Sermorelin was not placed on the 503A Category 2 list in 2023 and is not on the 503A bulks list; many 503A pharmacies compound it on the basis of the former approval, and whether that satisfies the component of an approved drug condition depends on how a state board and the pharmacy read it. Compounded sermorelin for adult anti-aging, fat loss, or sleep is an unapproved use with no supporting trial.	FDA approved as Egrifta (tesamorelin for injection) on November 10, 2010, for reduction of excess abdominal fat in HIV infected adults with lipodystrophy; Egrifta SV, a 2 mg vial formulation, was approved in 2019, and Egrifta WR, an 11.6 mg vial formulation, in March 2025. Tesamorelin is a 44 amino acid protein, and on March 23, 2020 FDA deemed the Egrifta application (022505) to be a biologics license. FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin sold by telehealth and anti-aging clinics has no lawful basis, and Egrifta WR by prescription is the only lawful product. A clinician may prescribe Egrifta WR off-label, but use for fat loss in people without HIV has only limited trial support.
WADA	WADA: WADA prohibited	WADA: WADA prohibited
Routes	Subcutaneous injection, usually at bedtime (approved and trial use), Intravenous bolus (former diagnostic use), Intranasal (research only, lower bioavailability), Oral tablets and troches sold by some compounders have no published pharmacokinetic data	Subcutaneous injection into the abdomen once daily (Egrifta WR, Egrifta SV), No oral, sublingual, or nasal form is FDA approved or tested in a published trial
Typical cost	About 105 to 180 USD per month for compounded sermorelin through licensed telehealth programs, including the consultation and medication. Research chemical listings are not lawful for human use. Prices checked 2026-09-22 on published provider and pharmacy price pages.	Egrifta WR has no published list price; a retail cash listing put one 28 day kit at about 10,709 USD, and a manufacturer co-pay program helps eligible commercially insured patients with the approved HIV indication. Compounded tesamorelin has no lawful price, because tesamorelin is a biologic and biologics cannot be compounded. Prices checked 2026-09-22.
Last verified	Sep 23, 2026	Sep 23, 2026

Has sermorelin been tested directly against tesamorelin?

No published trial has compared sermorelin and tesamorelin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do sermorelin and tesamorelin cost?

Typical cost of Sermorelin and Tesamorelin
Dimension	Sermorelin	Tesamorelin
Typical cost	$105 to $180 per month	$10,709 per month
Price detail	Sermorelin price by channel	Tesamorelin price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is tesamorelin just a stronger sermorelin?

Both activate the GHRH receptor, but tesamorelin is the full 44 amino acid hormone with a protective chemical group, so it lasts longer, and it has been tested in large phase 3 trials. Sermorelin is the 29 amino acid fragment with a half life of minutes. [3] [5] [7]

Tesamorelin vs sermorelin: which works better?

Tesamorelin, on the evidence. It cut visceral fat by 15.4% relative to placebo in 806 adults with HIV and by about 35 cm2 in a 60 person trial of abdominal obesity without HIV. Sermorelin's best adult trial had 19 people and measured hormone levels, skin thickness, and lean mass in men, not fat loss. Only tesamorelin has a current FDA approval. [1] [5] [12] [15]

Which is better for belly fat?

Tesamorelin is the only one with trial evidence: in people with HIV it reduced visceral fat by 15.4% relative to placebo over 26 weeks. Outside HIV, one 60 person trial in abdominal obesity with reduced growth hormone secretion found a similar visceral fat drop with tesamorelin. No trial has tested sermorelin for visceral fat. [1] [5] [15]

Is either FDA approved?

Tesamorelin is, as Egrifta WR and Egrifta SV for HIV associated abdominal fat. Sermorelin was approved as Geref but the approvals were withdrawn in 2009; FDA later determined that was not for safety or effectiveness reasons. [8] [12]

Why is compounded sermorelin so much cheaper than Egrifta?

Branded Egrifta WR has no published list price, and one retail cash listing put a 28 day kit at about 10,709 USD (checked 2026-09-22). Compounded sermorelin is paid in cash at a small fraction of that; it is not an FDA approved formulation and is not tested the way a branded product is. Compounded tesamorelin is not a lawful option at any price, because tesamorelin is a biologic and biologics cannot be compounded. [10] [14] [16]

Can athletes use either?

No. Both are growth hormone releasing hormone analogs prohibited at all times under WADA section S2. [11]

Conditions studied

From the blog

Sermorelin vs HGH: mechanism, evidence, and legal status
Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label.
Tesamorelin vs HGH: how they differ and which is approved
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
Does tesamorelin build muscle? What the trials show
Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport.
How to get peptides prescribed legally in 2026
Which peptides a licensed prescriber can lawfully write for today, which are waiting on an FDA rule, how telehealth rules work, and the red flags that mean a product is not a prescription at all.
Tesamorelin before and after: what the trials measured
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.
Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 23). Sermorelin vs tesamorelin: evidence, cost, and legality. https://peptideagent.ai/compare/sermorelin-vs-tesamorelin
HTML link: <a href="https://peptideagent.ai/compare/sermorelin-vs-tesamorelin">Sermorelin vs tesamorelin: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.

Sermorelin vs tesamorelin (tesamorelin vs sermorelin)

The short answer